 Shares of Altimmune Inc. were down 4.1 in trading on Thursday, the day after the clinical-stage company said it had received regulatory approval to begin studying its COVID-19 vaccine candidate in a Phase 1 clinical trial. Altimmune said Wednesday the Food and Drug Administration had OKed the companys investigational new drug application for its experimental single-dose, intranasal vaccine. 